Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.52 |
| ▸ | TOP1 | P11387 | 2/20 | 0.36 |
| ▸ | CYCS | P99999 | 2/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914167 | 0.99 | TERT (0.51) | TERTTOP1CYCSENPP2 | |
| SCHEMBL29935687 | 0.99 | TERT (0.51) | TERTTOP1CYCSENPP2 | |
| Hydrochloric Acid SCHEMBL4753685 | 0.97 | TERT (0.53) | TERTTOP1CYCS | |
| Hydrochloric Acid SCHEMBL4753666 | 0.97 | TERT (0.50) | TERTTOP1CYCSENPP2 | |
| SCHEMBL450264 | 0.90 | TERT (0.48) | TERTTOP1CYCSENPP2 | |
| SCHEMBL452379 | 0.87 | TERT (0.46) | TERTTOP1 | |
| SCHEMBL6007193 | 0.86 | STAT3 (0.49) | TERT | |
| SCHEMBL452116 | 0.85 | NPC1 (0.45) | TERT | |
| SCHEMBL30096016 | 0.85 | NPC1 (0.45) | TERT | |
| SCHEMBL448359 | 0.85 | NPC1 (0.45) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148749-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | PASTEUR INSTITUT (FR) | 2024-05-09 | — | — | US | disclosed |
| EP-4308107-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | INSTITUT PASTEUR (FR) | 2024-01-24 | — | — | EP | disclosed |
| WO-2022195100-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | INSTITUT PASTEUR (FR) | 2022-09-22 | — | — | WO | disclosed |
| US-11058666-B2 | Oral administration of melanin for protection against radiation | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190298692-A1 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2019-10-03 | — | — | US | disclosed |
| US-10251915-B2 | Co-encapsulation of live cells with oxygen-generating particles | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170354691-A1 | CO-ENCAPSULATION OF LIVE CELLS WITH OXYGEN-GENERATING PARTICLES | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2017-12-14 | — | — | US | disclosed |
| US-9775866-B2 | Co-encapsulation of live cells with oxygen-generating particles | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170128497-A1 | CO-ENCAPSULATION OF LIVE CELLS WITH OXYGEN-GENERATING PARTICLES | WAKE FOREST UNIV HEALTHY SCIENCES (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170128416-A1 | ORAL ADMINISTRATION OF MELANIN FOR PROTECTION AGAINST RADIATION | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-1439842-A1 | OXIDANT SCAVENGERS FOR TREATMENT OF DIABETES OR USE IN TRANSPLANTATION OR INDUCTION OF IMMUNE TOLERANCE | National Jewish Medical and Research Center (US) | 2004-07-28 | — | — | EP | disclosed |
| US-20040058902-A1 | Substituted porphyrins | DUKE UNIVERSITY | 2004-03-25 | — | — | US | disclosed |
| EP-1045851-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20030050297-A1 | Cancer therapy | GOODNOW CAPITAL, L.L.C. | 2003-03-13 | — | — | US | disclosed |
| US-20030032634-A1 | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance | GOODNOW CAPITAL, L.L.C. | 2003-02-13 | — | — | US | disclosed |
| WO-2002098431-A1 | OXIDANT SCAVENGERS FOR TREATMENT OF DIABETES OR USE IN TRANSPLANTATION OR INDUCTION OF IMMUNE TOLERANCE | NATIONAL JEWISH MEDICAL AND RESEARCH CENTER (US) | 2002-12-12 | — | — | WO | disclosed |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | DUKE UNIVERSITY | 2002-04-11 | — | — | US | disclosed |
| EP-1045851-A4 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1045851-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 2000-10-25 | — | — | EP | disclosed |
| WO-1999023097-A1 | SUBSTITUTED PORPHYRINS | DUKE UNIVERSITY (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148749-A1 | MNTBAP AND M(III)N-SUBSTITUTED PYRIDYLPORPHYRINS(MNPS)FOR USE IN REVERSING SEPSIS-INDUCED MICROGLIAL CELLS ALTERATIONS AND/OR FOR TREATING SEPSIS OR SEPSIS-ASSOCIATED ENCEPHALOPATHY | PEBP1, TPX2, MPEG1 | TERT 1233/4885TOP1 3489/4885CYCS 4397/4885 |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | LPO, PRDX5, MPO | TERT 3237/4885TOP1 4338/4885CYCS 265/4885 |
| US-20030050297-A1 | Cancer therapy | SOD1, SOD3, GPX1 | TERT 76/4885TOP1 465/4885CYCS 150/4885 |
| US-20040058902-A1 | Substituted porphyrins | SOD1, SOD3, CAT | TERT 1933/4885TOP1 2957/4885CYCS 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.